Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

1.266 -0.004 (-0.31%)
Streaming Delayed Price Updated: 9:43 AM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in September Investor and Industry Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with... 
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.